Chronic Lymphocytic Leukemia - Epidemiology Forecast to 2023, New Report Launched

Chronic lymphocytic leukemia (CLL), also known as chronic lymphoid leukemia, is a type of cancer of the white blood cells (lymphocytes). CLL affects a particular lymphocyte, the B cell, which accumulates mainly in the bone marrow and blood, and normally fights infection. In CLL, the DNA of a B cell is damaged, so that it cannot fight infection, but it grows out of control and affects the healthy blood cells that can fight infection (NCI, 2013a). The natural history of this enigmatic disease is heterogeneous, where some patients live out their lives not requiring treatment and die of causes not related to CLL, whereas others have rapidly progressive disease requiring treatment within months of diagnosis (Wierda et al., 2007). CLL accounts for 30% of all adult leukemia and is the most common form of leukemia in the western world, with an average annual incidence of 5.0 cases per 100,000 population in people of all ages (Hallek and Pflug, 2010). CLL is primarily a disease of the elderly population, with less than 10% of the cases below 40 years of age (Hallek and Pflug, 2010). Although the condition is more common in the elderly population, many patients with CLL have long lives and die of causes unrelated to the disease (Dighiero et al., 1998).

This report provides an overview of the risk factors, comorbidities, and the global and historical trends for CLL in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, the report also includes a 10-year epidemiological forecast of the diagnosed incident cases of CLL segmented by age (at 10-year intervals starting at age 40 years and ending at ages ≥80 years) and sex. Publisher epidemiologists also forecast the 5-year diagnosed prevalent cases of CLL in the 6MM. Additionally, the report provides CLL diagnosed incident cases segmented by Rai stage at diagnosis for the 6MM. To forecast the diagnosed incident and 5-year diagnosed prevalent cases of CLL in the 6MM, Publisher epidemiologists selected nationally representative population-based studies that provided diagnosed incidence or relative survival rates of CLL in the 6MM. Relative survival rates are used to calculate the 5-year diagnosed prevalent cases of CLL.

Publisher epidemiologists forecast an increase in the diagnosed incident cases of CLL in the 6MM, from 37,795 diagnosed incident cases in 2013 to 45,683 diagnosed incident cases in 2023, with an annual growth rate (AGR) of 2.09% during the forecast period.In 2023, the US will have the highest number of diagnosed incident cases of CLL in the 6MM with 19,844 diagnosed incident cases, whereas Spain will have the fewest number of diagnosed incident cases of CLL with 2,710 diagnosed incident cases.

Similarly, the 5-year diagnosed prevalent cases of CLL in the 6MM increased from 150,800 diagnosed prevalent cases in 2013 to 183,165 diagnosed prevalent cases in 2023, with an AGR of 2.15% during the forecast period. Because Publisher epidemiologists held the diagnosed incidence of CLL and the relative survival rates of CLL constant throughout the forecast period, population changes in the respective markets are driving the increase in the diagnosed incident cases of CLL and the 5-year diagnosed prevalent cases of CLL in these markets during the forecast period.

Know more about this report at: http://mrr.cm/ZGm

Find other Pharma and Healthcare Reports at : 

http://www.marketresearchreports.com/pharma-healthcare